Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Delta inulin is a biocompatible polysaccharide particle derived from poly(fructo-furanosyl) α-d-glucose. It is an immunologically active and temperature-stable isoform of inulin that acts as a potent immune adjuvant. Delta inulin enhances both humoral and cellular immune responses to co-administered antigens by activating the complement system and binding to monocytes, thereby regulating chemokine production and cell surface protein expression[1][6]. Its mechanism of action involves binding to the dendritic cell–specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) receptor on antigen-presenting cells, which helps activate and boost adaptive immunity[5]. Delta inulin has been used as the basis for Advax, a vaccine adjuvant evaluated for use with vaccines against influenza, hepatitis B, Japanese encephalitis, West Nile virus, HIV, anthrax, Listeria, and insect-sting allergy[2][8]. It is safe and well tolerated when administered subcutaneously or intramuscularly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on delta inulin.